Name | Number of supported studies | Average coverage | |
---|---|---|---|
club cell | 11 studies | 62% ± 26% | |
ciliated cell | 10 studies | 48% ± 25% | |
respiratory goblet cell | 8 studies | 47% ± 25% | |
basal cell | 7 studies | 47% ± 29% | |
type I pneumocyte | 6 studies | 42% ± 11% | |
natural killer cell | 5 studies | 26% ± 4% | |
ionocyte | 5 studies | 50% ± 30% | |
endothelial cell of lymphatic vessel | 5 studies | 34% ± 13% | |
fibroblast | 5 studies | 27% ± 13% | |
type II pneumocyte | 5 studies | 37% ± 15% | |
mast cell | 4 studies | 23% ± 4% | |
epithelial cell | 4 studies | 38% ± 14% | |
secretory cell | 4 studies | 59% ± 38% | |
deuterosomal cell | 3 studies | 48% ± 10% | |
CD8-positive, alpha-beta T cell | 3 studies | 36% ± 12% | |
capillary endothelial cell | 3 studies | 42% ± 7% | |
conventional dendritic cell | 3 studies | 26% ± 3% | |
endothelial cell of artery | 3 studies | 33% ± 12% | |
pericyte | 3 studies | 31% ± 4% | |
smooth muscle cell | 3 studies | 20% ± 2% | |
vein endothelial cell | 3 studies | 36% ± 10% | |
macrophage | 3 studies | 36% ± 11% | |
endothelial cell | 3 studies | 30% ± 13% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 7 studies | 42% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 11199.68 | 576 / 578 | 51% | 158.63 | 587 / 1155 |
prostate | 92% | 560.04 | 225 / 245 | 38% | 15.03 | 192 / 502 |
esophagus | 41% | 22.65 | 599 / 1445 | 9% | 5.90 | 17 / 183 |
brain | 30% | 2.80 | 795 / 2642 | 0% | 0 | 0 / 705 |
ovary | 7% | 9.19 | 12 / 180 | 22% | 12.47 | 93 / 430 |
pancreas | 16% | 6.09 | 53 / 328 | 4% | 0.94 | 7 / 178 |
uterus | 6% | 6.15 | 11 / 170 | 12% | 9.21 | 55 / 459 |
bladder | 5% | 0.86 | 1 / 21 | 11% | 28.27 | 55 / 504 |
thymus | 12% | 2.07 | 77 / 653 | 1% | 0.80 | 5 / 605 |
heart | 13% | 1.34 | 108 / 861 | 0% | 0 | 0 / 0 |
breast | 10% | 1.68 | 48 / 459 | 1% | 0.29 | 12 / 1118 |
intestine | 8% | 3.03 | 77 / 966 | 2% | 0.72 | 13 / 527 |
peripheral blood | 10% | 71.75 | 96 / 929 | 0% | 0 | 0 / 0 |
adipose | 10% | 3.50 | 124 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 8% | 3.28 | 113 / 1335 | 0% | 0 | 0 / 0 |
skin | 8% | 0.93 | 138 / 1809 | 1% | 4.52 | 3 / 472 |
muscle | 8% | 0.86 | 66 / 803 | 0% | 0 | 0 / 0 |
liver | 8% | 0.89 | 17 / 226 | 0% | 0.44 | 2 / 406 |
stomach | 7% | 0.70 | 24 / 359 | 1% | 0.15 | 2 / 286 |
tonsil | 0% | 0 | 0 / 0 | 7% | 3.09 | 3 / 45 |
adrenal gland | 5% | 0.91 | 13 / 258 | 0% | 0 | 0 / 230 |
spleen | 3% | 0.57 | 7 / 241 | 0% | 0 | 0 / 0 |
kidney | 1% | 0.67 | 1 / 89 | 0% | 0.03 | 1 / 901 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0042098 | Biological process | T cell proliferation |
GO_0034097 | Biological process | response to cytokine |
GO_0007165 | Biological process | signal transduction |
GO_0010193 | Biological process | response to ozone |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0007565 | Biological process | female pregnancy |
GO_0071774 | Biological process | response to fibroblast growth factor |
GO_0051384 | Biological process | response to glucocorticoid |
GO_0032696 | Biological process | negative regulation of interleukin-13 production |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0032713 | Biological process | negative regulation of interleukin-4 production |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_0032714 | Biological process | negative regulation of interleukin-5 production |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0034021 | Biological process | response to silicon dioxide |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0007566 | Biological process | embryo implantation |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005635 | Cellular component | nuclear envelope |
GO_0005737 | Cellular component | cytoplasm |
GO_0030141 | Cellular component | secretory granule |
GO_0019834 | Molecular function | phospholipase A2 inhibitor activity |
GO_0097160 | Molecular function | polychlorinated biphenyl binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SCGB1A1 |
Protein name | Uteroglobin (Secretoglobin family 1A member 1) Uteroglobin (Club cell phospholipid-binding protein) (CCPBP) (Club cells 10 kDa secretory protein) (CC10) (Secretoglobin family 1A member 1) (Urinary protein 1) (UP-1) (UP1) (Urine protein 1) Secretoglobin family 1A member 1 isoform 2 |
Synonyms | CC10 UGB CCSP |
Description | FUNCTION: Binds phosphatidylcholine, phosphatidylinositol, polychlorinated biphenyls (PCB) and weakly progesterone, potent inhibitor of phospholipase A2. |
Accessions | P11684 A0A0S2Z4R6 A0A0S2Z4L0 E9PN95 ENST00000534397.5 ENST00000278282.3 |